Skip to content
  • Publications
  • Training
  • FAQs
  • M&E Dashboard
  • Vacancies
Menu
  • Publications
  • Training
  • FAQs
  • M&E Dashboard
  • Vacancies
Contact
  • COVID-19
    • SARS-COV-2 Rapid Test Reporting
    • TrakCare Lab Webview
    • COVID-19 Frequently Asked Questions
    • COVID-19 Returning to Work FAQs
    • COVID-19 Surveillance Reports
    • COVID-19 Vaccine
    • Variant Tracking in South Africa
    • COVID-19 Technical Resources
    • COVID-19 Guidelines
    • COVID-19 Advice for The Public
    • COVID-19 Prevention
    • COVID-19 Advice for Travellers
    • Long COVID
    • COVID-19 Vaccine Breakthrough Cases Frequently Asked Questions
    • COVID-19 Resources for Children
    • COVID-19 Communication Resources
    • COVID-19 Contact Resources
  • About Us
    • Overview
    • Our Objectives
    • Management
    • Our Partners
    • Data protection and privacy policy
  • Centres
    • Centre for Emerging Zoonotic and Parasitic Diseases
    • Centre for Enteric Diseases
    • Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses
    • Centre for HIV and STIs
    • Centre for Respiratory Diseases and Meningitis
    • Centre for Tuberculosis
    • Centre for Vaccines and Immunology
    • Division of Public Health, Surveillance and Response
    • National Cancer Registry
      • Cancer Statistics
    • Transversal Functions
  • Our Services
    • Surveillance
    • Training
    • Outbreak Response
    • Research
    • Proficiency Testing Schemes
    • Diagnostic Services
  • Notifiable Medical Conditions
    • Overview
    • Notification Process
    • Tutorial Videos
    • Notification Forms
    • NMC COVID-19 Documents
    • Contacts
  • Media
    • Alerts
    • News
    • Videos
    • Podcasts
    • Blogs
Menu
  • COVID-19
    • SARS-COV-2 Rapid Test Reporting
    • TrakCare Lab Webview
    • COVID-19 Frequently Asked Questions
    • COVID-19 Returning to Work FAQs
    • COVID-19 Surveillance Reports
    • COVID-19 Vaccine
    • Variant Tracking in South Africa
    • COVID-19 Technical Resources
    • COVID-19 Guidelines
    • COVID-19 Advice for The Public
    • COVID-19 Prevention
    • COVID-19 Advice for Travellers
    • Long COVID
    • COVID-19 Vaccine Breakthrough Cases Frequently Asked Questions
    • COVID-19 Resources for Children
    • COVID-19 Communication Resources
    • COVID-19 Contact Resources
  • About Us
    • Overview
    • Our Objectives
    • Management
    • Our Partners
    • Data protection and privacy policy
  • Centres
    • Centre for Emerging Zoonotic and Parasitic Diseases
    • Centre for Enteric Diseases
    • Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses
    • Centre for HIV and STIs
    • Centre for Respiratory Diseases and Meningitis
    • Centre for Tuberculosis
    • Centre for Vaccines and Immunology
    • Division of Public Health, Surveillance and Response
    • National Cancer Registry
      • Cancer Statistics
    • Transversal Functions
  • Our Services
    • Surveillance
    • Training
    • Outbreak Response
    • Research
    • Proficiency Testing Schemes
    • Diagnostic Services
  • Notifiable Medical Conditions
    • Overview
    • Notification Process
    • Tutorial Videos
    • Notification Forms
    • NMC COVID-19 Documents
    • Contacts
  • Media
    • Alerts
    • News
    • Videos
    • Podcasts
    • Blogs
Search
Close
Search
Close
  • OVERVIEW
  • OUR OBJECTIVES
  • MANAGEMENT
  • OUR PARTNERS
  • DATA PROTECTION AND PRIVACY POLICY
Menu
  • OVERVIEW
  • OUR OBJECTIVES
  • MANAGEMENT
  • OUR PARTNERS
  • DATA PROTECTION AND PRIVACY POLICY

NICD-Carbapenam-resistant bacteria

Diseases A-Z Index NICD-Carbapenam-resistant bacteria

Diseases A-Z Index:
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • W
  • V
  • X
  • Y
  • Z

Carbapenem–resistant bacteria are resistant to carbapenem antibiotics. These Gram-negative bacteria are usually from the genera known as Klebsiella, Enterobacter, Escherichia, but other genera also become resistant to carbapenems. Bacteria are highly adaptive organisms. Carbapenem antibiotics are broad-spectrum beta-lactam-type antibiotics that are especially effective against Gram-negative bacteria. Carbapenem antibiotics were introduced in the early 1980s and were seen as the last line of defence against Gram-negative bacteria that had become resistant to multiple other antibiotics. Examples of carbapenem antibiotics include imipenem, meropenem, ertapenem and doripenem. Over time, Gram-negative bacteria developed resistance to carbapenem antibiotics. They have gained the ability to either break down carbapenems with an enzyme (“carbapenemases”), or to prevent the antibiotic from entering its cell or to transport it out of the cell. In this way, carbapenem antibiotics can no longer kill these bacteria. The problem is that now, infections with these Gram-negative bacteria are essentially untreatable.

Carbapenem-resistant bacteria-Frequently Asked Questions (2018)

Share

Share on facebook
Share on twitter
Facebook Instagram Linkedin Twitter Youtube

Quick Links

  • M&E Dashboard
  • Publications
  • Vacancies
  • Researcher Directory
  • Terms and Conditions

Download NMC

  • Android App
  • Huawei App
  • Web Portal
  • Apple App

Connect with our Researchers

Contact Us

© NICD 2021. All Rights Reserved
Disclaimer: The National Institute for Communicable Diseases does not provide Medical Advice to the public. For Medical Advice, please consult your Healthcare provider.